Anti-Tumor Potential of AEV01 in Glioma: In Vitro and Xenograft Model Studies
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Gliomas are difficult to treat with short survival rates despite current therapies. The need for new treatments is urgent, and orthotopic cell-derived tumor xenograft (CDX) models have provided valuable insights. AEV01, a specialty extract from the roots of Picrorhiza kurroa, shows promise as a non-surgical treatment option with anti-inflammatory, antioxidant, and anti-cancer properties. Its efficacy has been demonstrated in a patient with pancreatic cancer and in enhancing immune conditions in COVID-19 patients.
Objectives
This study was conducted with the objective to investigate the anti-tumour properties of AEV01 in human glioblastoma through in vitro and in vivo experiments.
Methodology
The methodology of the study involved the use cell lines namely HEK-293T and U-87 MG glioblastoma. The cytotoxicity of the drug AEV01 was assessed using the MTT assay. Dual staining with acridine orange/ethidium bromide was performed to evaluate morphological changes in the cancer cells. ELISA was used to detect protein marker expression levels. Immunocytochemistry was employed to assess CD36 expression in various cellular models. Orthotopic tumor engraftment was carried out to establish a glioblastoma-induced model. Animal grouping and treatment plans were done, and histopathological effects were evaluated. Immunohistochemistry was performed to assess the anti-tumor effects of AEV01. ELISA and toxicity studies were also conducted.
Results
The results of the study showed that AEV01 had dose-dependent cytotoxicity against glioma, while minimally impacting normal cells. AEV01 induced apoptosis in cancer cells and downregulated the expression of inflammatory markers while upregulating the expression of the tumor suppressor protein TP53. AEV01 also decreased the expression of CD36, a potential target for cancer therapy, in glioma cancer cells. In an in vivo glioma-induced model, AEV01 exhibited anti-tumor effects and reduced the expression of CD36. Histopathological analysis demonstrated that AEV01 had minimal toxicity on vital organs. Overall, these findings suggest that AEV01 has potential as a therapeutic agent for glioma.
